ANEBULO PHARMAC. DL-001
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical tria… Read more
Market Cap & Net Worth: ANEBULO PHARMAC. DL-001 (214)
ANEBULO PHARMAC. DL-001 (F:214) has a market capitalization of $44.38 Million (€43.23 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #32342 globally and #3609 in its home market, demonstrating a 211.76% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ANEBULO PHARMAC. DL-001's stock price €1.06 by its total outstanding shares 40784731 (40.78 Million).
ANEBULO PHARMAC. DL-001 Market Cap History: 2021 to 2026
ANEBULO PHARMAC. DL-001's market capitalization history from 2021 to 2026. Data shows change from $223.97 Million to $44.38 Million (-29.98% CAGR).
ANEBULO PHARMAC. DL-001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ANEBULO PHARMAC. DL-001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 214 by Market Capitalization
Companies near ANEBULO PHARMAC. DL-001 in the global market cap rankings as of March 19, 2026.
Key companies related to ANEBULO PHARMAC. DL-001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ANEBULO PHARMAC. DL-001 Historical Marketcap From 2021 to 2026
Between 2021 and today, ANEBULO PHARMAC. DL-001's market cap moved from $223.97 Million to $ 44.38 Million, with a yearly change of -29.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €44.38 Million | -21.48% |
| 2025 | €56.52 Million | +39.90% |
| 2024 | €40.40 Million | -57.30% |
| 2023 | €94.61 Million | -5.83% |
| 2022 | €100.47 Million | -55.14% |
| 2021 | €223.97 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ANEBULO PHARMAC. DL-001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $44.38 Million USD |
| MoneyControl | $44.38 Million USD |
| MarketWatch | $44.38 Million USD |
| marketcap.company | $44.38 Million USD |
| Reuters | $44.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.